AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28301687
Drug: Ozone therapy
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozone therapy (OG) for overall VAS scores from baseline to 3 months.
Trial: 25894894
Drug: JNJ-38893777 (doses:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-38893777 (doses: 5, 15, 45, 125, 250, or 500 mg)
Trial: 25894894
Drug: JNJ-38893777 (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-38893777 (250 mg in fasting state and 250 mg, 375 mg, or 500 mg in high-fat fed state)
Trial: 21429223
Drug: Single intradermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intradermal sterile water injection (SWI) technique
Trial: 21429223
Drug: Four intradermal
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four intradermal sterile water injection (SWI) technique
Trial: 15220018
Drug: Glimepiride +
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glimepiride + Pioglitazone (G + P)
Trial: 15220018
Drug: Glimepiride +
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glimepiride + Rosiglitazone (G + R)
Trial: 9640189
Drug: Latanoprost monotherapy
RxNorm normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Latanoprost monotherapy (50 micrograms/ml)
Trial: 9640189
Drug: Dipivefrin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipivefrin monotherapy (1 mg/ml)
Trial: 9640189
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of latanoprost and dipivefrin
Trial: 7979527
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of cromoglycate three times a day by wet nebulisation (n = 16)
Trial: 1147500
Drug: Intravenous diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous diazepam preoperatively
Trial: 31743136
Drug: Propofol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (2 to 3 mg/kg)
Trial: 31743136
Drug: Etomidate (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etomidate (0.2 to 0.3 mg/kg)
Trial: 24060106
Drug: Attention-control group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attention-control group (bi-monthly telephone contact)
Trial: 15316094
Drug: Everolimus 0.75
RxNorm normalized name: everolimus 0.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 0.75 mg/day
Trial: 15316094
Drug: Everolimus 2.5
RxNorm normalized name: everolimus 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 2.5 mg/day
Trial: 21232120
Drug: Everolimus 5
RxNorm normalized name: everolimus 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 5 mg/day
Trial: 9109044
Drug: Tirilazad mesylate
RxNorm normalized name: tirilazad mesylate
DrugBank: Tirilazad (DB13050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirilazad mesylate 10.0 mg/kg/day for 5 days
Trial: 3539631
Drug: Ambroxol (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambroxol (90 mg orally for 14 days)
Trial: 29692607
Drug: Indacaterol/glycopyrronium (IND/GLY)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indacaterol/glycopyrronium (IND/GLY) 110/50 μg
Trial: 24525630
Drug: Bilateral suprazygomatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral suprazygomatic maxillary nerve block with 0.15 ml/kg of 0.2% ropivacaine
Trial: 22632908
Drug: 0.9 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 mg/kg intravenous recombinant tissue plasminogen activator (rt-PA)
Trial: 20710058
Drug: JTK-652 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JTK-652 (100 mg three times daily for 4 weeks)
Trial: 17050021
Drug: Imagery rehearsal
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imagery rehearsal in addition to normal physical therapy (12 individual sessions)
Trial: 11904107
Drug: Calcium (1
RxNorm normalized name: hydroxyapatite 275 mg calcium (1,100 mg) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (1 g/d, n = 111)
Trial: 1455195
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of Cyclosporin
Trial: 1455195
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of Cyclosporin
Trial: 30829137
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (50,000 IU weekly for 16 weeks)
Trial: 29986492
Drug: Fortified corn-soy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fortified corn-soy blend (CSB+) with multiple-micronutrient supplement (CSB+UNIMMAP)
Trial: 23802706
Drug: Q8003 (morphine/oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Q8003 (morphine/oxycodone combination) 12 mg/8 mg
Trial: 23802706
Drug: morphine 12 mg
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: morphine 12 mg
Trial: 23802706
Drug: oxycodone 8 mg
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oxycodone 8 mg
Trial: 20226390
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (mean dose, 528 IU/d)
Trial: 20226390
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D plus calcium therapy (from Women's Health Initiative Randomized Trial)
Trial: 19138241
Drug: Sildenafil citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil citrate (100 mg, single dose)
Trial: 24382963
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) therapy
Trial: 10843168
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) therapy after placebo
Trial: 7702136
Drug: Diamorphine 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diamorphine 3 mg in bolus with bupivacaine 10 ml of 0.25% followed by infusion of bupivacaine 0.1% at 10 ml.h‐1
Trial: 7702136
Drug: Diamorphine 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diamorphine 3 mg in infusion with bupivacaine 10 ml of 0.25% followed by infusion of bupivacaine 0.1% at 10 ml.h‐1
Trial: 678393
Drug: Amitriptyline 6.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline 6.25 mg
Trial: 678393
Drug: Amitriptyline 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline 12.5 mg
Trial: 678393
Drug: Nortriptyline 25
RxNorm normalized name: nortriptyline 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nortriptyline 25 mg
Trial: 678393
Drug: Protriptyline 10
RxNorm normalized name: protriptyline 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protriptyline 10 mg
Trial: 678393
Drug: BW247 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BW247 12.5 mg
Trial: 678393
Drug: BW247 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BW247 25 mg
Trial: 31475493
Drug: Acupuncture plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture plus medication (Mannitol Injection 125 mL every 8 hours, Oxiracetam Injection 4 g once a day)
Trial: 31475493
Drug: Medication (Mannitol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (Mannitol Injection 125 mL every 8 hours, Oxiracetam Injection 4 g once a day)
Trial: 26152604
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose dabigatran (110mg bid)
Trial: 18580126
Drug: Physical methods
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical methods of antipyresis (e.g., cooling blankets)
Trial: 12680909
Drug: Motilin infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Motilin infusion (8 pmol (kg min)(-1) for 5 min)
Trial: 12680909
Drug: Motilin infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Motilin infusion following an antral phase III
Trial: 8421029
Drug: Intravenous dose
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dose of cephamandole at the time of tourniquet deflation
Trial: 3534590
Drug: Full-dose sequential
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose sequential non-cross-resistant combinations
Trial: 26845175
Drug: Trabectedin (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabectedin (1.2 mg/m2 administered over 24 h on day 1 of a 21-d treatment cycle)
Trial: 24020826
Drug: Preservative-free timolol
RxNorm normalized name: Preservative-Free timolol 5 MG/ML Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preservative-free timolol gel
Trial: 12860778
Drug: Sertraline hydrochloride,
RxNorm normalized name: Sertraline Hydrochloride, 25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline hydrochloride, mean dosage of 95 mg/d
Trial: 10668525
Drug: Leflunomide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leflunomide (20 mg/day after a loading dose of 100 mg/day for 3 days)
Trial: 10668525
Drug: Methotrexate (7.5‐15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (7.5‐15 mg/week)
Trial: 6426992
Drug: Almitrine bismesylate
RxNorm normalized name: almitrine dimesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almitrine bismesylate 100 mg orally
Trial: 19388819
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg dapivirine from intravaginal ring (IVR)
Trial: 19388819
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg dapivirine from intravaginal ring (IVR)
Trial: 19388819
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg dapivirine from IVR
Trial: 19388819
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg dapivirine from IVR
Trial: 19388819
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg and 25 mg dapivirine from IVR
Trial: 17465499
Drug: Parameters influencing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parameters influencing fibrosis and treatment response
Trial: 15633894
Drug: Cetirizine hydrochloride
RxNorm normalized name: Cetirizine Hydrochloride
DrugBank: Cetirizine (DB00341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cetirizine hydrochloride (10 mg by mouth daily for 1 week)
Trial: 11444086
Drug: Fluvastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin (40 mg daily) + Vitamin C (500 mg)
Trial: 7999527
Drug: MgSO4 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MgSO4 (20 mg/kg over 10 min, followed by 10 mg/kg/h)
Trial: 7999527
Drug: MgSO4 and
RxNorm normalized name: MgSO4
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MgSO4 and Saline infusion
Trial: 3141642
Drug: Fybogel (Ispaghula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fybogel (Ispaghula husk), one sachet twice daily
Trial: 28777771
Drug: Family-based cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-based cognitive-behavioral therapy delivered through the Internet
Trial: 25197005
Drug: Albuterol and
RxNorm normalized name: Albuterol and cromolyn only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol and ipratropium (combined therapy)
Trial: 25197005
Drug: Dual bronchodilator
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual bronchodilator therapy (albuterol and ipratropium)
Trial: 25197005
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (pre-dose values)
Trial: 24557960
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy with amoxicillin and lansoprazole for the first 5 days and clarithromycin, ornidazole and lansoprazole for another 5 days.
Trial: 24557960
Drug: Standard triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard triple therapy with amoxicillin, clarithromycin, and lansoprazole for 14 days.
Trial: 8396534
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg of MK-0679
Trial: 3750367
Drug: Ready-to-use solution
DrugBank: Sodium phosphate, dibasic, unspecified form (DB14504)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ready-to-use solution
Trial: 29377592
Drug: Dairy protein
RxNorm normalized name: Beano Dairy Defense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dairy protein supplementation (20 g d-1)
Trial: 18809153
Drug: rosuvastatin 20
RxNorm normalized name: rosuvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin 20 mg/day
Trial: 22531237
Drug: DTaP-IPV-Hep B-PRP-T
RxNorm normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTaP-IPV-Hep B-PRP-T vaccine (group 1)
Trial: 22531237
Drug: Licensed DTwP-Hep
RxNorm normalized name: heparin sodium, porcine Injectable Solution [Hep-Pak]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licensed DTwP-Hep B//Hib and oral poliovirus vaccines (group 2)
Trial: 20447541
Drug: Elevated H‐FABP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elevated H‐FABP levels (> or =6 ng/ml)
Trial: 20447541
Drug: Low H‐FABP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low H‐FABP levels (<6 ng/ml)
Trial: 20447541
Drug: H‐FABP levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H‐FABP levels (median 11.2 ng/ml)
Trial: 11997276
Drug: Adjunctive PCI
RxNorm normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive PCI of open (TFG 2/3) arteries
Trial: 2367159
Drug: Intramuscular gamma-globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular gamma-globulin treatment
Trial: 28730418
Drug: 1 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 μg IV low dose cosyntropin test
Trial: 28730418
Drug: 25 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 μg IM medium dose cosyntropin test
Trial: 28730418
Drug: 250 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 μg IM standard dose cosyntropin test (30 min)
Trial: 28730418
Drug: 250 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 μg IM standard dose cosyntropin test (60 min)
Trial: 31529070
Drug: Insulin tolerance
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin tolerance test
Trial: 18751690
Drug: Nevirapine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nevirapine (200 mg twice daily) with rifampicin-based tuberculosis therapy
Trial: 18751690
Drug: Nevirapine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nevirapine (200 mg twice daily) without rifampicin-based tuberculosis therapy
Trial: 10496303
Drug: Oral valganciclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral valganciclovir 450, 875, 1750 and 2625 mg once daily for 3 days
Trial: 10496303
Drug: Oral valganciclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral valganciclovir 900 mg/day
Trial: 8768808
Drug: Red wine
RxNorm normalized name: Red wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red wine with 3,700 micrograms histamine/l
Trial: 8768808
Drug: Red wine
RxNorm normalized name: Red wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red wine with 200 micrograms histamine/l
Trial: 2015149
Drug: lignocaine 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lignocaine 0.1 mg kg‐1
Trial: 2015149
Drug: lignocaine 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lignocaine 0.2 mg kg‐1
Trial: 2015149
Drug: lignocaine 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lignocaine 0.4 mg kg‐1
Trial: 6258871
Drug: APE (adriamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APE (adriamycin 35 mg/m2 IV D1 Q 3 weeks; procarbazine 60 mg/m2 PO D1-10 Q 3 weeks; VP16-213 130 mg/m2 IV D8, 15 Q 3 weeks)
Trial: 6258871
Drug: MOCC (methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOCC (methotrexate 15 mg/m2 IV or PO twice weekly D8-21 Q 3 weeks; Oncovin 1.5 mg/m2 IV D8, 15 Q 3 weeks; cyclophosphamide 600 mg/m2 IV D1 Q 3 weeks; CCNU 60 mg/m2 PO Q 6 weeks)
Trial: 25930049
Drug: Primary care-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary care-based treatment visit
Trial: 24460645
Drug: Enoxaparin 40
RxNorm normalized name: ENOXAPARIN 40MG/0.4ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 40 mg once daily for 10 ± 4 days then placebo up to day 35
Trial: 22832965
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy (CBT) for 15 weeks
Trial: 19299767
Drug: Arndt wire‐guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arndt wire‐guided bronchial blocker (BB)
Trial: 19299767
Drug: Cohen Flexi‐tip
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohen Flexi‐tip bronchial blocker (BB)
Trial: 19299767
Drug: Fuji Uni‐blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fuji Uni‐blocker (BB)
Trial: 9690731
Drug: Spironolactone 100
RxNorm normalized name: spironolactone 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone 100 mg daily for 7 days
Trial: 9690731
Drug: Theophylline 250
RxNorm normalized name: theophylline 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline 250 mg on days 1, 2, 4 and 6
Trial: 277678
Drug: Topical 2%
RxNorm normalized name: menthol topical 2% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 2% sodium fluoride
Trial: 277678
Drug: Combined strontium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined strontium and fluoride treatment
Trial: 31163551
Drug: Adrenalin saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenalin saline local injection (5 ml, concentration 1:200,000)
Trial: 25271172
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) metronidazole, 15 mg/kg
Trial: 16952493
Drug: Ibuprofen (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (600 mg 3 times daily)
Trial: 14973303
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl (2.5 microg/kg)
Trial: 3565116
Drug: Advised in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advised in advance of the biological test
Trial: 3565116
Drug: Live explanation
RxNorm normalized name: fecal microbiota, live Enema [Rebyota]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live explanation and demonstration of the biological testing procedure
Trial: 12145792
Drug: Combination endoscopic
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination endoscopic therapy (with epinephrine injection, shaving down the clot with cold guillotining, and bipolar coagulation on the underlying stigmata)
Trial: 9651664
Drug: celiprolol (beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: celiprolol (beta 1‐ and beta 2‐adrenoceptor partial agonist)
Trial: 9651664
Drug: propranolol (beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: propranolol (beta 1‐ and beta 2‐adrenoceptor antagonist)
Trial: 9651664
Drug: atenolol (beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atenolol (beta 1‐adrenoceptor antagonist)
Trial: 2646846
Drug: Cimetidine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (600 mg p.o. + 200 mg i.m.)
Trial: 2646846
Drug: Ranitidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (150 mg p.o. + 50 mg i.m.)
Trial: 28318636
Drug: Control Group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Group (no treatment)
Trial: 15002083
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate 500 mg twice daily for 2 weeks
Trial: 11708573
Drug: Policosanol 5
RxNorm normalized name: policosanol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Policosanol 5 mg/day for 8 weeks
Trial: 11708573
Drug: Policosanol 10
RxNorm normalized name: policosanol 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Policosanol 10 mg/day for the next 8 weeks
Trial: 9144826
Drug: Interventions for
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interventions for preventing aggression including a protocol for talking to patients, discussing treatment goals, explaining locked door policies, providing staff meeting schedules, and clarifying appointment procedures.
Trial: 3309074
Drug: Ibuprofen (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (10 mg/kg) administered 30 min before amphotericin B
Trial: 30663869
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg baricitinib